单抗药-话题@MedSci

#单抗药#

36篇内容 | 1642人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1707118, encodeId=16791e07118b9, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=Clinical Translational Gastroenterology：克罗恩病患者接受诱导治疗后高阿达木单抗药物水平可在第24周仍保持患者的生物缓解, objectType=article, longId=219255, objectId=ce6b219255e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6b219255e2, replyNumber=0, likeNumber=72, createdTime=2022-04-05, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6b219255e2, moduleTitle=Clinical Translational Gastroenterology：克罗恩病患者接受诱导治疗后高阿达木单抗药物水平可在第24周仍保持患者的生物缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6b219255e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707117, encodeId=000b1e0711744, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=Clin Trans Gastroenterology:诱导治疗后高阿达木单抗药物水平可预测克罗恩病患者第 24 周的疾病生物学缓解, objectType=article, longId=218242, objectId=cbb32182425b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbb32182425b, replyNumber=0, likeNumber=87, createdTime=2022-04-27, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbb32182425b, moduleTitle=Clin Trans Gastroenterology:诱导治疗后高阿达木单抗药物水平可预测克罗恩病患者第 24 周的疾病生物学缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbb32182425b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707115, encodeId=b1511e07115c9, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=JAMA：还在为偏头痛而烦恼吗？来看看“宝藏”单抗药物的神奇疗效！, objectType=article, longId=212830, objectId=2275212830cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2275212830cd, replyNumber=0, likeNumber=72, createdTime=2021-10-06, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2275212830cd, moduleTitle=JAMA：还在为偏头痛而烦恼吗？来看看“宝藏”单抗药物的神奇疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2275212830cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707116, encodeId=2e0d1e07116f3, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=IBD:英夫利昔单抗药物浓度较高可改善克罗恩病患者的血液和粪便中性粒细胞生物标志物的情况, objectType=article, longId=212976, objectId=9c3d2129e64b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c3d2129e64b, replyNumber=0, likeNumber=102, createdTime=2022-01-17, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c3d2129e64b, moduleTitle=IBD:英夫利昔单抗药物浓度较高可改善克罗恩病患者的血液和粪便中性粒细胞生物标志物的情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c3d2129e64b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707114, encodeId=73831e07114fc, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, objectType=article, longId=207999, objectId=50a420e99915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50a420e99915, replyNumber=0, likeNumber=81, createdTime=2021-07-18, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50a420e99915, moduleTitle=抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50a420e99915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707112, encodeId=a9bf1e0711269, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=IBD: 英夫利昔单抗药物浓度达标可改善克罗恩病中中性粒细胞的水平, objectType=article, longId=201955, objectId=933a201955e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933a201955e2, replyNumber=0, likeNumber=93, createdTime=2021-09-17, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933a201955e2, moduleTitle=IBD: 英夫利昔单抗药物浓度达标可改善克罗恩病中中性粒细胞的水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933a201955e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707113, encodeId=9e2d1e07113de, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=JCC：细菌和真菌谱可以作为炎症性肠病患者对于英夫利昔单抗药物反应的标志物, objectType=article, longId=204585, objectId=92ba204585a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92ba204585a7, replyNumber=0, likeNumber=85, createdTime=2021-04-08, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92ba204585a7, moduleTitle=JCC：细菌和真菌谱可以作为炎症性肠病患者对于英夫利昔单抗药物反应的标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92ba204585a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707111, encodeId=f1651e07111b3, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188491, objectId=478e18849102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=478e18849102, replyNumber=0, likeNumber=49, createdTime=2020-04-05, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=478e18849102, moduleTitle=战疫中——单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=478e18849102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707110, encodeId=78531e0711075, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=战疫中 - 单抗药和 Remdesivir 组合是救星吗？, objectType=article, longId=188271, objectId=3b261882e1e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b261882e1e3, replyNumber=0, likeNumber=86, createdTime=2020-10-26, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b261882e1e3, moduleTitle=战疫中 - 单抗药和 Remdesivir 组合是救星吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b261882e1e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707109, encodeId=71021e0710970, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=IBD：主动监测英夫利昔单抗药物疗效优于炎症性肠病的常规治疗, objectType=article, longId=186476, objectId=48e41864e6ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48e41864e6ea, replyNumber=0, likeNumber=64, createdTime=2020-12-15, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48e41864e6ea, moduleTitle=IBD：主动监测英夫利昔单抗药物疗效优于炎症性肠病的常规治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48e41864e6ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707108, encodeId=280f1e0710875, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=IBD：克罗恩病维持治疗期间阿达木单抗药物水平升高与生物学缓解相关, objectType=article, longId=165622, objectId=ddd9165622be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddd9165622be, replyNumber=0, likeNumber=77, createdTime=2020-03-24, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddd9165622be, moduleTitle=IBD：克罗恩病维持治疗期间阿达木单抗药物水平升高与生物学缓解相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddd9165622be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707107, encodeId=07e91e0710796, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=AP&T：老年IBD患者使用抗肿瘤坏死因子α和维多珠单抗药物效果一样出色, objectType=article, longId=164331, objectId=cce81643312a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cce81643312a, replyNumber=0, likeNumber=74, createdTime=2019-11-14, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cce81643312a, moduleTitle=AP&T：老年IBD患者使用抗肿瘤坏死因子α和维多珠单抗药物效果一样出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cce81643312a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707106, encodeId=5a181e0710636, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=Blood: 5年长期联合使用全反式视黄酸+三氧化砷+吉妥珠单抗药物治疗急性早幼粒细胞白血病的跟踪报道, objectType=article, longId=91764, objectId=6f1891e6454, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f1891e6454, replyNumber=0, likeNumber=79, createdTime=2017-08-02, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f1891e6454, moduleTitle=Blood: 5年长期联合使用全反式视黄酸+三氧化砷+吉妥珠单抗药物治疗急性早幼粒细胞白血病的跟踪报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f1891e6454)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707103, encodeId=918b1e07103d0, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=喜讯！欧盟CHMP支持批准礼来单抗药olaratumab联合阿霉素治疗晚期软组织肉瘤, objectType=article, longId=77801, objectId=cf7be780188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf7be780188, replyNumber=0, likeNumber=82, createdTime=2016-10-26, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf7be780188, moduleTitle=喜讯！欧盟CHMP支持批准礼来单抗药olaratumab联合阿霉素治疗晚期软组织肉瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf7be780188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707104, encodeId=537a1e07104d6, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=【新近进展】国内PD-1单抗药物进入临床二期, objectType=article, longId=83059, objectId=d4638305942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4638305942, replyNumber=0, likeNumber=64, createdTime=2017-05-30, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4638305942, moduleTitle=【新近进展】国内PD-1单抗药物进入临床二期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4638305942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707105, encodeId=75121e071054a, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=Cancer Res：HDAC抑制剂可促进单抗药物对HER2阳性肿瘤的治疗效果, objectType=article, longId=90949, objectId=ebb19094974, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebb19094974, replyNumber=0, likeNumber=93, createdTime=2017-04-15, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebb19094974, moduleTitle=Cancer Res：HDAC抑制剂可促进单抗药物对HER2阳性肿瘤的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebb19094974)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707101, encodeId=2cd91e0710179, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=再生元单抗药物fasinumab治疗骨关节炎痛II/III临床获得成功, objectType=article, longId=67504, objectId=57616e504b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57616e504b2, replyNumber=0, likeNumber=78, createdTime=2016-06-08, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57616e504b2, moduleTitle=再生元单抗药物fasinumab治疗骨关节炎痛II/III临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57616e504b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707100, encodeId=53701e07100e4, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=FDA批准单抗药Arzerra治疗复发性CLL, objectType=article, longId=62378, objectId=cbef623e83a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbef623e83a, replyNumber=0, likeNumber=77, createdTime=2016-02-26, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbef623e83a, moduleTitle=FDA批准单抗药Arzerra治疗复发性CLL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbef623e83a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707102, encodeId=ea3a1e071027c, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=FDA授予礼来单抗药物olaratumab治疗晚期软组织肉瘤的优先审查资格, objectType=article, longId=67744, objectId=aa4d6e74471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa4d6e74471, replyNumber=0, likeNumber=77, createdTime=2017-04-05, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa4d6e74471, moduleTitle=FDA授予礼来单抗药物olaratumab治疗晚期软组织肉瘤的优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa4d6e74471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1707099, encodeId=258f1e0709924, content=<a href='/topic/show?id=1db9361966e' target=_blank style='color:#2F92EE;'>#单抗药#</a>, objectTitle=新一代降脂单抗药PCSK9呼之欲出, objectType=article, longId=52297, objectId=a02d5229e21, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a02d5229e21, replyNumber=0, likeNumber=64, createdTime=2015-11-15, rootId=0, userName=12498636m59(暂无昵称), userId=9b8a31348863, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a02d5229e21, moduleTitle=新一代降脂单抗药PCSK9呼之欲出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a02d5229e21)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

单抗药

2020-05-29

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

Clinical Translational Gastroenterology：克罗恩病患者接受诱导治疗后高阿达木单抗药物水平可在第24周仍保持患者的生物缓解

2022-04-05

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

Clin Trans Gastroenterology:诱导治疗后高阿达木单抗药物水平可预测克罗恩病患者第 24 周的疾病生物学缓解

2022-04-27

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

JAMA：还在为偏头痛而烦恼吗？来看看“宝藏”单抗药物的神奇疗效！

2021-10-06

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

IBD:英夫利昔单抗药物浓度较高可改善克罗恩病患者的血液和粪便中性粒细胞生物标志物的情况

2022-01-17

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

抗PD-1单抗药物“派安普利”III期临床试验中期显示优异结果

2021-07-18

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

IBD: 英夫利昔单抗药物浓度达标可改善克罗恩病中中性粒细胞的水平

2021-09-17

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

JCC：细菌和真菌谱可以作为炎症性肠病患者对于英夫利昔单抗药物反应的标志物

2021-04-08

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

战疫中——单抗药和 Remdesivir 组合是救星吗？

2020-04-05

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

战疫中 - 单抗药和 Remdesivir 组合是救星吗？

2020-10-26

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

IBD：主动监测英夫利昔单抗药物疗效优于炎症性肠病的常规治疗

2020-12-15

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

IBD：克罗恩病维持治疗期间阿达木单抗药物水平升高与生物学缓解相关

2020-03-24

12498636m59(暂无昵称) (审核中...)

前往app查看评论内容

#单抗药#

AP&T：老年IBD患者使用抗肿瘤坏死因子α和维多珠单抗药物效果一样出色

2019-11-14

12498636m59(暂无昵称) (审核中...)